Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The New England Journal of Medicine

- PMLiVE

FDA grants priority review to Biogen’s tofersen for genetic form of ALS

The approval follows a failed phase 3 study, but the treatment showed promise in patients with SOD1-ALS

- PMLiVE

Sandoz’s application for MS biosimilar accepted by FDA

The proposed ‘first-of-a-kind’ biosimilar matched the reference medicine, Biogen’s Tysabri, in terms of efficacy, safety and immunogenicity

- PMLiVE

FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease

Lecanmab is being evaluated in the ongoing phase 3 Clarity Alzheimer's clinical trial

- PMLiVE

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment

NRG received a £2.68m Innovative UK award to help fund research into treatments for Parkinson’s disease, motor neurone disease and other neurodegenerative diseases

- PMLiVE

Bristol Myers Squibb announces positive trial results for treatment of MS

In the two phase 3 trials, Zeposia treatment showed improved or preserved cognitive function in the majority of patients

- PMLiVE

Biogen and Happify Health team up to create digital platform for MS patients

There are over 2.3 million people living with MS worldwide, with women being more likely to develop the condition than men

- PMLiVE

Six UK universities receive grant for research into motor neurone disease

The grant was given by the Medical Research Council and the National Institute for Health and Care Research, along with charities LifeArc, MND Association, My Name’5 Doddie Foundation and MND...

- PMLiVE

Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease

The new approach would allow doctors to identify the disease at an early stage and provide treatment and support to patients sooner

- PMLiVE

TauRx shares phase 3 trial data for Alzheimer’s drug

Those receiving the drug experienced a significantly slower decline than usual

- PMLiVE

EIT Health and Biogen announce winners of first ‘neurotechprize’

The winners, Five Lives and Neurocast, were among ten finalists working to create tech solutions for Alzheimer’s disease

- PMLiVE

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme

- PMLiVE

Biogen and MedRhythms sign deal worth over $120m for digital therapeutics for MS patients

The collaboration is focused on improving MS patients’ mobility and walking

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links